SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME

 

• BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC.

• Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically significant superiority of ibrexafungerp over placebo for primary and key secondary endpoints.

https://finance.yahoo.com/news/scynexis-announces-fda-approval-second-130000442.html